

FACT SHEET

Dorsal Root Ganglion Stimulation

For treatment of pain associated with complex regional pain syndrome (CRPS)

CHRONIC PAIN

Chronic pain is a largely under-treated and misunderstood disease that affects millions of people worldwide. It is defined as moderate to severe pain that persists for six months or longer than would generally be expected for recovery to a specific disease, injury or surgery. According to the National Institutes of Health, 90 million people in the U.S. suffer from chronic pain. The American Pain Foundation estimates that chronic pain costs approximately \$100 billion per year in lost work time and health care expenses. In their search for relief, some patients often endure inadequate treatments and struggle with prescription opioid painkillers.

CHRONIC PAIN CONDITIONS

One chronic pain condition that impact millions is Complex Regional Pain Syndrome (CRPS). This condition is one of the most difficult types of pain to treat because of complexity, intensity and location. Called the “suicide disease” by patient advocacy groups, CRPS is a progressive disease of the nervous system and involves peripheral nerve pain following surgery or injury.

‘PACEMAKER FOR PAIN’

Spinal cord stimulation (SCS) is a proven therapy recommended by physicians to help patients manage their chronic pain and improve quality of life. Spinal cord stimulators are implanted devices that are similar in function and appearance to cardiac pacemakers, except that the electrical pulses are sent to the spinal cord instead of the heart. These “pacemakers for pain” interrupt the pain signals’ pathways to the brain by delivering mild electrical pulses. Neurostimulation has shown to provide relief so patients can focus on their lives instead of their pain.

DORSAL ROOT GANGLION (DRG) STIMULATION

DRG stimulation is a new type of neurostimulation therapy that targets and relieves pain. By stimulating the DRG, physicians can treat the specific areas of the body where pain occurs. This makes the therapy effective for patients living with CRPS who have been unsuccessfully treated by therapy, medication or traditional SCS.

IMPROVING PATIENT CARE WITH DRG THERAPY

Abbott is committed to patient-centric innovation in neuromodulation. The market leader in chronic pain, Abbott is the only company in the world approved to offer DRG stimulation. DRG stimulation therapy is available on the Proclaim™ DRG Neurostimulation System. The system is magnetic resonance (MR)-conditional and recharge free, meaning patients do not need to be reminded of their condition and pause from their daily activities to charge their battery as with other systems. Using Bluetooth wireless connectivity, patients can feel empowered by controlling their stimulation levels through a familiar Apple iPod Touch device.

DRIVING INNOVATION WITH CLINICAL EVIDENCE

DRG therapy has an extensive history of rigorous scientific research. Over 508 patients in 13-plus studies have been published in peer-reviewed journals. The ACCURATE IDE study of Abbott’s DRG therapy was the largest clinical trial to date evaluating patients with CRPS. The ACCURATE study, which was used to gain FDA approval, showed that DRG therapy provided significant pain relief to 8 out of 10 people at 12 months.¹ It also showed greater treatment success when compared to patients receiving traditional tonic SCS.

¹Deer, TR, Levy, RM, Kramer, J, et al. (2017). Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. *Pain*. 158(4): 669-681. <http://dx.doi.org/10.1097/j.pain.0000000000000814> ACCURATE IDE STUDY, St. Jude Medical. (n=152).

Important safety information: <https://abbo.tt/2uEA6YG>

**Note: iPad mini and iPad Touch are registered trademarks of Apple, Inc. Bluetooth is a registered trademark of Bluetooth SIG, Inc.*



ABBOTT MEDIA CONTACT:
MICKI SIEVWRIGHT
651-756-4615
MICKI.SIEVWRIGHT@ABBOTT.COM